ADHD medications may reduce risk of early death, major study suggests

Review of 19 studies involving more than 15 million participants finds higher mortality risks for those with ADHD, but medication associated with lower risk

By LineZotpaper

Published20 October 2026

Read Time2 min

A large review published in JAMA Network Open has found that people with ADHD face a significantly higher risk of early death from any cause, including suicide, injury and natural causes. However, the study also suggests that prescription medications used to treat ADHD are associated with a lower risk of death among those with the disorder.

Researchers from institutions across the United Kingdom analysed 19 existing studies published between 2012 and 2025, covering populations in the United States, Canada, Sweden, Taiwan, the United Kingdom, Finland and Denmark. Together, the data encompassed more than 15.9 million participants, allowing the team to pool results and identify patterns less likely to occur by chance.

The pooled analysis found that people with ADHD had a 70 percent higher hazard of death from any cause compared to people without the condition. The risk of death from suicide was 90 percent higher, the risk of death from unintentional or intentional injury was 50 percent higher, and even the risk of death from natural causes was 30 percent higher. These findings generally align with an earlier review, though that review did not find evidence for increased mortality from natural causes. The authors suggested the difference may reflect the inclusion of more recent studies or variations in study designs.

Encouragingly, the review also found that prescription medications used to treat ADHD, primarily stimulants, were associated with a lower risk of death from any cause in ADHD populations. The study did not distinguish between effects of different medications.

The researchers cautioned that the methods are not intended to show cause and effect, and that the observed associations may be influenced by factors such as gender balance across studies, cultural attitudes, healthcare differences between countries, and changes in ADHD diagnosis and management over time. "Pooled estimates should be interpreted as average associations across diverse populations and study contexts rather than as being universally applicable," the authors noted.

The review highlights that multiple factors may increase mortality risk for people with ADHD. The researchers concluded that the evidence reinforces the importance of support for managing health risks in this population and attention to addressing structural determinants of poor health disproportionately experienced by people with ADHD.

Analysis

Why This Matters

The study provides some of the strongest evidence to date that ADHD is linked to a higher risk of premature death, underscoring the serious health implications of the condition.
The finding that medication may reduce mortality risk could influence treatment decisions and public health strategies, encouraging better access to diagnosis and prescription.
With ADHD affecting an estimated 5 percent of children and 2.5 percent of adults globally, even modest reductions in mortality risk could have a significant population-level impact.

Background

ADHD is a neurodevelopmental disorder characterised by inattention, impulsivity and hyperactivity. These traits can lead to difficulties with focus and planning, which may contribute to accidents, missed healthcare appointments, and unhealthy behaviours. Previous research has linked ADHD to increased mortality, but the role of medication in modifying that risk has been less clear. The new review pools a large volume of international data to examine both risks and potential protective effects of treatment.

Key Perspectives

People with ADHD and their families: The findings offer reassurance that treatment may have life-saving benefits beyond symptom control, though they highlight the importance of consistent healthcare access. Healthcare providers: Clinicians may consider the mortality findings when discussing treatment options with patients, while remaining mindful that the review is observational and does not prove causation. Researchers: The study authors stress that pooled estimates average across diverse populations and that structural factors, such as healthcare access and social determinants, likely play a role. They call for further research into specific medications and underlying mechanisms.

What to Watch

Further studies that distinguish between types of ADHD medications, particularly non-stimulant options, and their specific effects on mortality.
Policy discussions around improving healthcare access and support for people with ADHD, especially in countries with limited mental health resources.
Updated clinical guidelines that may incorporate mortality risk and treatment benefits into recommendations.

Sources

ADHD Drugs May Reduce The Risk of Early Death, Major Study Finds · ScienceAlert

Checked

12 claims in this story checked against 1 source: 12 supported.

Show each claim

SupportedADHD medications may reduce risk of early death, major study suggestsScienceAlert: “The review also suggests ADHD medication may reduce the risk of early death among those living with the disorder.”
SupportedReview of 19 studies involving more than 15 million participants finds higher mortality risks for those with ADHD, but medication associated with lower riskScienceAlert: “reviewed 19 existing studies ... more than 15.9 million participants ... people with ADHD had a 70 percent higher hazard of death ... prescription medications ... are associated with a lower risk”
SupportedPeople with ADHD had a 70 percent higher hazard of death from any cause compared to people without the conditionScienceAlert: “People with ADHD had a 70 percent higher hazard of death from any cause than people without the condition.”
SupportedThe risk of death from suicide was 90 percent higher, the risk of death from unintentional or intentional injury was 50 percent higher, and the risk of death from natural causes was 30 percent higherScienceAlert: “The risk of death from suicide was 90 percent higher among people with ADHD. Their risk of death from unintentional or intentional injury was 50 percent higher, and even the risk of death from natural causes was 30 percent higher.”
SupportedA large review published in JAMA Network OpenScienceAlert: “A large review published in JAMA Network Open”
SupportedResearchers from institutions across the United Kingdom analysed 19 existing studies published between 2012 and 2025, covering populations in the United States, Canada, Sweden, Taiwan, the United Kingdom, Finland and DenmarkScienceAlert: “Researchers from institutions across the UK reviewed 19 existing studies published between 2012 and 2025. Each study ... populations from across the world: the US, Canada, Sweden, Taiwan, the UK, Finland, and Denmark.”
SupportedTogether, the data encompassed more than 15.9 million participantsScienceAlert: “more than 15.9 million participants”
SupportedThese findings generally align with an earlier review, though that review did not find evidence for increased mortality from natural causes. The authors suggested the difference may reflect the inclusion of more recent studies or variations in study designsScienceAlert: “These findings generally agree with the results of an earlier review, except for the part about deaths from natural causes. ... 'This difference may reflect the inclusion of more recently published studies or differences in the studies and effect estimates included,' the authors suggest.”
SupportedPrescription medications used to treat ADHD, primarily stimulants, were associated with a lower risk of death from any cause in ADHD populations. The study did not distinguish between effects of different medicationsScienceAlert: “The good news is that prescription medications used to treat ADHD are associated with a lower risk of death from any cause in ADHD populations. The study doesn't distinguish between the effects of different medications, but generally, stimulants are the drugs prescribed for ADHD.”
SupportedThe researchers cautioned that the methods are not intended to show cause and effect, and that the observed associations may be influenced by factors such as gender balance across studies, cultural attitudes, healthcare differences between countries, and changes in ADHD diagnosis and management over timeScienceAlert: “The methods used for this research are not intended to show cause and effect ... The authors also saw a lot of variation between studies, which might be related to factors like the balance of gender in study populations, the cultural attitudes and healthcare services in different countries, and changes in ADHD diagnosis and management over the past decade or so.”
Supported"Pooled estimates should be interpreted as average associations across diverse populations and study contexts rather than as being universally applicable," the authors notedScienceAlert: “'Pooled estimates should be interpreted as average associations across diverse populations and study contexts rather than as being universally applicable,' the authors note.”
SupportedThe review highlights that multiple factors may increase mortality risk for people with ADHD. The researchers concluded that the evidence reinforces the importance of support for managing health risks in this population and attention to addressing structural determinants of poor health disproportionately experienced by people with ADHDScienceAlert: “'The current evidence suggests that there are multiple factors that may increase risk for mortality outcomes in people with ADHD, reinforcing the importance of support for managing health risks in this population and attention to addressing structural determinants of poor health disproportionately experienced by people with ADHD,' the authors conclude.”

Correction

20 October 2026An earlier version of this story presented a paraphrase of the researchers’ conclusion as a direct quote.